Increased Remission Rates After Long-Term Methimazole Therapy in Patients with Graves' Disease: Results of a Randomized Clinical Trial

被引:73
|
作者
Azizi, Fereidoun [1 ]
Amouzegar, Atieh [1 ]
Tohidi, Maryam [2 ]
Hedayati, Mehdi [3 ]
Khalili, Davood [2 ,4 ]
Cheraghi, Leila [4 ]
Mehrabi, Yadollah [5 ]
Takyar, Miralireza [1 ]
机构
[1] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Endocrine Res Ctr, POB 19395-4763, Tehran 1985717413, Iran
[2] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Prevent Metab Disorders Res Ctr, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Cellular & Mol Endocrine Res Ctr, Tehran, Iran
[4] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Dept Epidemiol & Biostat, Tehran, Iran
[5] Shahid Beheshti Univ Med Sci, Sch Publ Hlth & Safety, Dept Epidemiol & Biostat, Tehran, Iran
关键词
long-term; methimazole; Graves' disease; remission rates; ANTITHYROID DRUG-TREATMENT; HYPERTHYROIDISM; EXPOSURE; IODINE; RISK;
D O I
10.1089/thy.2019.0180
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Studies differ regarding whether, compared with courses of conventional duration, longer-term antithyroid drug treatment increases frequency of remission in patients with Graves' hyperthyroidism. We prospectively conducted a randomized, parallel-group study comparing relapse rates in patients receiving longer-term versus conventional-length methimazole therapy. We also sought variables associated with relapse following the latter. Methods: We enrolled 302 consecutive patients with untreated first episodes of Graves' hyperthyroidism. After 18-24 months of methimazole, 258 patients (85.4%) were randomized to an additional 36-102-month courses ("long-term group": n = 130; scheduled total time on methimazole: 60-120 months) or discontinuation of methimazole ("conventional group": n = 128). Patients were followed 48 months postmethimazole cessation. We performed Cox proportional hazards modeling to identify factors associated with relapse after conventional courses. Results: Methimazole was given for 95 +/- 22 months in long-term patients and 19 +/- 3 months in the conventional group. Fourteen patients experienced cutaneous reactions and 2 liver enzyme elevations during the first 18 months of treatment; no further methimazole-related reactions were observed despite therapy for up to another 118 months. Hyperthyroidism recurred within 48 months postmethimazole withdrawal in 15% (18/119) of long-term patients versus 53% (65/123) of conventional group patients. In the conventional group, older age, higher triiodothyronine or thyrotropin receptor antibody concentrations, lower thyrotropin concentration, or possession of the rs1879877 CD28 polymorphism or the DQB1-05 HLA polymorphism were independently associated with relapse. Conclusion: Administration of low-dose methimazole for a total of 60-120 months safely and effectively treats Graves' hyperthyroidism, with much higher remission rates than those attained by using conventional 18-24-month courses.
引用
收藏
页码:1192 / 1200
页数:9
相关论文
共 50 条
  • [21] Long-term results following functionally optimized readioiodine therapy in Graves'disease
    Dunkelmann, S.
    Timpte, B.
    Toepfer, M.
    Kurth, J.
    Groth, P.
    Schuemichen, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S349 - S349
  • [22] Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance
    Atkinson, AB
    Kennedy, A
    Wiggam, MI
    McCance, DR
    Sheridan, B
    CLINICAL ENDOCRINOLOGY, 2005, 63 (05) : 549 - 559
  • [23] METAANALYSIS EVALUATION OF THE IMPACT OF THYROTROPIN RECEPTOR ANTIBODIES ON LONG-TERM REMISSION AFTER MEDICAL THERAPY OF GRAVES-DISEASE
    FELDTRASMUSSEN, U
    SCHLEUSENER, H
    CARAYON, P
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 78 (01): : 98 - 102
  • [24] Long-term methimazole therapy in Graves' hyperthyroidism and adverse reactions: a Danish multicenter study
    Karmisholt, J.
    Andersen, S. L.
    Bulow-Pedersen, I
    Krejbjerg, A.
    Nygaard, B.
    Carle, A.
    EUROPEAN THYROID JOURNAL, 2022, 11 (03)
  • [25] "Effects of Low-dose Methotrexate With Methimazole in Patients With Graves' Disease: Results of a Randomized Clinical Trial" (Jul, dgae472, 2024)
    Xie, P.
    Shen, L.
    Peng, R.
    Wang, Y.
    Yin, Q.
    Chen, X.
    Jin, Z.
    Ning, G.
    Wang, W.
    Wang, S.
    Zhou, Y.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024,
  • [26] LONG-TERM RESULTS OF RADIOIODINE (I-131) THERAPY IN 331 PATIENTS WITH GRAVES-DISEASE
    SAITO, S
    SAKURADA, T
    YAMAMOTO, M
    YOSHIDA, K
    KAISE, K
    KAISE, N
    YOSHINAGA, K
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 1980, 132 (01): : 1 - 10
  • [27] Outcome of complications in acromegaly patients after long-term disease remission
    Claessen, Kim M. J. A.
    Pereira, Alberto M.
    Biermasz, Nienke R.
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2015, 10 (05) : 499 - 510
  • [28] Long-Term Engagement of Patients With Advanced Cancer: Results From the EPAC Randomized Clinical Trial
    Patel, Manali I.
    Agrawal, Madhuri
    Blayney, Douglas W.
    Bundorf, M. Kate
    Milstein, Arnold
    JAMA ONCOLOGY, 2024, 10 (07) : 905 - 911
  • [29] Long-Term Follow-up of Graves Orbitopathy After Treatment With Short- or Long-Term Methimazole or Radioactive Iodine
    Azizi, Fereidoun
    Abdi, Hengameh
    Mehran, Ladan
    Perros, Petros
    Masoumi, Safdar
    Amouzegar, Atieh
    ENDOCRINE PRACTICE, 2023, 29 (04) : 240 - 246
  • [30] Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial
    Lundell, L
    Havu, N
    Miettinen, P
    Myrvold, HE
    Wallin, L
    Julkunen, R
    Levander, K
    Hatlebakk, JG
    Liedman, B
    Lamm, M
    Malm, A
    Walan, A
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (05) : 639 - 647